Efficacy and Safety of Combination Therapy with Anticancer Drugs in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

• Combination therapy (e.g., atezolizumab plus bevacizumab) significantly improves overall survival and progression-free survival in unresectable hepatocellular carcinoma compared to sorafenib. • Objective response rates are more than doubled with combination therapy, indicating enhanced antitumor activity. • The increased risk of grade ≥3 adverse events is manageable with appropriate monitoring and supportive care. • These results establish combination therapy as a new first-line standard for unresectable HCC, potentially improving long-term outcomes.